BioRestorative Therapies
Yahoo Finance • 7 days ago
Biotech Stocks Shine After Hours: Novo Nordisk, IDEAYA, Healthcare Triangle Among Gainers
(RTTNews) - Healthcare and biotechnology stocks saw notable moves in after-hours trading on Monday, with several companies posting strong gains despite limited news flow. Novo Nordisk A/S (NVO) surged in extended trading, climbing 9.48% t... Full story
Yahoo Finance • last month
BioRestorative Granted Type B Meeting with FDA to Discuss Accelerated BLA Approval Pathway for BRTX-100 in Chronic Lumbar Disc Disease
MELVILLE, N.Y., Nov. 17, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a regenerative medicine innovator focused on stem cell-based therapies and products, today announ... Full story
Yahoo Finance • 2 months ago
BioRestorative outlines BioCosmeceuticals expansion with new leadership and eyes $63B market opportunity
Earnings Call Insights: BioRestorative Therapies, Inc. (BRTX) Q3 2025 MANAGEMENT VIEW * Lance Alstodt, Chairman of the Board, President & CEO, emphasized, "we continue to execute well across all areas of our business in the third quart... Full story
Yahoo Finance • 2 months ago
After-Hours Biotech Watch: IFRX, ABCL, RLYB Among Notable Risers
(RTTNews) - Several biotechnology and pharmaceutical stocks showed notable price increases during Friday's after-hours trading session, with movement driven by upcoming data releases, recent earnings reports, and prior corporate updates.... Full story
Yahoo Finance • 2 months ago
BioRestorative Therapies to Report Third Quarter 2025 Financial Results and Host Conference Call on November 12, 2025
MELVILLE, N.Y., Nov. 05, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a regenerative medicine innovator focused on stem cell-based therapies and products, today announ... Full story
Yahoo Finance • 2 months ago
BioRestorative Awarded Notice of Allowance for Japanese Patent – Expands Protection for Potential Cell-Based Alternative to Multi-Billion Dollar GLP-1 Drug Market
MELVILLE, N.Y., Oct. 27, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a regenerative medicine innovator focused on stem cell-based therapies and products, today announ... Full story
Yahoo Finance • 2 months ago
BioRestorative Strengthens Commercial Leadership with Appointment of Crystal Romano as Head of Global Commercial Operations to Accelerate Growth of Cell-Based Product Portfolio
MELVILLE, N.Y., Oct. 22, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a regenerative medicine innovator focused on stem cell-based therapies and products, today announ... Full story
Yahoo Finance • 2 months ago
BioRestorative Therapies to Participate in the 2025 Maxim Growth Summit
MELVILLE, N.Y., Oct. 15, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a regenerative medicine innovator focused on stem cell-based therapies and products, is pleased t... Full story
Yahoo Finance • 3 months ago
BioRestorative CEO Lance Alstodt Interviewed on “The Big Biz Show”
MELVILLE, N.Y., Oct. 07, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a regenerative medicine innovator focused on stem cell-based therapies and products, today is ple... Full story
Yahoo Finance • 3 months ago
BioRestorative Therapies Announces $1.085 Million Registered Direct Offering Priced Above Market
MELVILLE, N.Y., Oct. 06, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, today announced it has entered in... Full story
Yahoo Finance • 5 months ago
BioRestorative Therapies earnings beat by $0.08, revenue fell short of estimates
Investing.com - BioRestorative Therapies (NASDAQ: BRTX) reported second quarter EPS of $-0.300, $0.08 better than the analyst estimate of $-0.380. Revenue for the quarter came in at $303K versus the consensus estimate of $340K. BioResto... Full story
Yahoo Finance • 5 months ago
BioRestorative Therapies GAAP EPS of -$0.30 beats by $0.07, revenue of $0.3M misses by $0.04M
* BioRestorative Therapies press release [https://seekingalpha.com/pr/20198632-biorestorative-therapies-reports-second-quarter-2025-financial-results-and-provides-business] (NASDAQ:BRTX [https://seekingalpha.com/symbol/BRTX]): Q2 GAAP EP... Full story
Yahoo Finance • 5 months ago
BioRestorative Therapies to Report Second Quarter 2025 Financial Results and Host Conference Call on August 12, 2025
MELVILLE, N.Y., Aug. 05, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage regenerative medicine innovator focused on stem cell-based therapies and product... Full story
Yahoo Finance • 6 months ago
BioRestorative to Participate in Benzinga All-Access Show Today to Discuss Compelling BRTX-100 Clinical Data, Leadership Enhancements and Strategic updates
MELVILLE, N.Y., June 18, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage regenerative medicine innovator focused on stem cell-based therapies and product... Full story
Yahoo Finance • 6 months ago
BioRestorative Announces Share Repurchase Program
MELVILLE, N.Y., June 17, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage regenerative medicine innovator focused on stem cell-based therapies and product... Full story
Yahoo Finance • 7 months ago
BioRestorative Reports Compelling Preliminary Data for FDA-Fast-Tracked BRTX-100 – an Autologous Stem Cell Therapy to Treat Chronic Lumbar Disc Disease
– The International Society for Stem Cell Research (“ISSCR”) 2025 Annual Meeting is the world’s foremost gathering of stem cell and regenerative medicine leaders – – Updated data presented at ISSCR 2025 demonstrates >50% improvement in pa... Full story
Yahoo Finance • 7 months ago
BioRestorative to Present Major Update on Promising Preliminary Phase 2 BRTX-100 Data at ISSCR 2025
– New blinded safety and efficacy data from 30 patients in ongoing Phase 2 trial to be unveiled June 13, 2025 – – ISSCR 2025 is the premier global event for stem cell research, drawing nearly 4,000 leaders from academia, biotech, and phar... Full story
Yahoo Finance • 8 months ago
Phase 2 Trial of BRTX-100 in cLDD Continues to Generate Positive Preliminary Blinded Data
MELVILLE, N.Y., May 13, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage regenerative medicine innovator focused on stem cell-based therapies and products... Full story
Yahoo Finance • 8 months ago
BioRestorative to Present a BRTX-100 Clinical Update at ISCT 2025
MELVILLE, N.Y., May 07, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage regenerative medicine innovator focused on stem cell-based therapies and products... Full story
Yahoo Finance • 8 months ago
BioRestorative to Participate in Benzinga All-Access Show Today to Discuss Recent Achievements of Key Clinical & Regulatory Milestones, and Highlight Commercial Opportunities
MELVILLE, N.Y., April 15, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage regenerative medicine innovator focused on stem cell-based therapies and produc... Full story
